Innorna, a clinical‑stage biotech company advancing RNA medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IN026 ...
IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA-LNP platform.HONG KONG SAR ...
Zacks Small Cap Research on MSN
PLX: 2025 full year results
By John Vandermosten, CFA NYSE: PLX READ THE FULL PLX RESEARCH REPORT 2025 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE: PLX) announced 2025 financial and operational results ...
Is it RA? Many ailments have similar symptoms. Here's what you need to know about health conditions that look like rheumatoid arthritis, but aren't.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results